Study to Investigate the Potential Drug-Drug Interaction Between ZSP1273 and Oseltamivir

Phase 1 Completed 36 enrolled Guangdong Raynovent Biotech Co., Ltd

RandomizedCrossoverOpen-labelBasic science

Summary

To evaluate the drug-drug interaction between ZSP1273 and oseltamivir, the pharmacokinetic characteristics and safety of ZSP1273 and oseltamivir in healthy subjects, so as to provide a basis for the design of administration regimen in subsequent clinical trials.

Timeline

Start: 2020-11-19
Primary completion: 2021-03-17
Completion: 2021-03-17

Publications

Pang Y, Li H, Chen X, Cao Y, Jiang H, Huang J, Liu Y. A phase I, single-center, randomized, open-label, three-period crossover study to evaluate the drug-drug interaction between ZSP1273 and oseltamivir in healthy Chinese subjects. Antimicrob Agents Chemother. 2025 Apr 2;69(4):e0172924. doi: 10.1128/aac.01729-24. Epub 2025 Feb 24.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Onradivir	Small molecule	600 mg	Oral
Subject	Oseltamivir	Small molecule	75 mg	Oral

Indications

No indication recorded.